Bionomics (ASX:BNO) has announced that it plans to conduct a registered initial public offering of shares in the US and a listing on Nasdaq.
The company said the number of shares and the price of the proposed offering have not yet been determined. It said the proposed offering is expected to commence after the US Securities and Exchange Commission completes its review process of a registration statement relating to the proposed offering that the company intends to file, and subject to market and other conditions, including the effectiveness of the Registration Statement and shareholder approval under Australian Securities Exchange (ASX) Listing Rule 7.1.
"No final decision has been made in respect of the Nasdaq listing and there can be no assurance as to the occurrence, timing or completion of such a listing. Following any Nasdaq listing Bionomics shares would continue to trade on ASX," said the company.
Bionomics' lead investigative candidate BNC210 is a novel, first-in-class, negative allosteric modulator of the α7 nicotinic acetylcholine receptor that is in development for the treatment of anxiety and stressor-related disorders.